A systematic review and meta-analysis of 32 studies
Reported outcomes from 4121 patients (over a median of 4 years) with adrenal incidentalomas.1
Reported outcomes from 4121 patients (over a median of 4 years) with adrenal incidentalomas.1
Patients with hypercortisolism experienced worsening comorbidities compared to patients with nonfunctioning adenomas.
Patients were grouped based on their dexamethasone suppression test (DST) cortisol levels at baseline and at study end.2
Patients with worsening DST ≥1.8 μg/dL had a 4x higher incidence of cardiovascular disease than those patients with DST <1.8 μg/dL
How to screen for hypercortisolism in patients with T2D
Up to 10% of patients with difficult-to-control T2D may have hypercortisolism3-5
Contact a rep and stay informed
References
1. Elhassan YS, Alahdab F, Prete A, et al. Ann Intern Med. 2019;171(2):107-116. doi:10.7326/M18-3630 2. Di Dalmazi G, Vivennati V, Garelli S, et al. Lancet Diabetes Endocrinol. 2014;2(5):396-405. doi:10.1016/S2213-8587(13)70211-0. 3. Chiodini I, Torlontano M, Scillitani A, et al. Eur J Endocrinol. 2005;153(6):837-844. doi:10.1530/eje.1.02045 4. Catargi B, Rigalleau V, Poussin A, et al. J Clin Endocrinol Metab. 2003;88(12):5808-5813. doi:10.1210/jc.2003-030254 5. Costa DS, Conceição FL, Leite NC, Ferreira MT, Salles GF, Cardoso CR. J Diabetes Complications. 2016;30(6):1032-1038. doi:10.1016/j.jdiacomp.2016.05.006